In clinical practice, pulmonary arterial hypertension (PAH) requires co-administration of multiple drugs to act on several pathogenic mechanisms; chronic pathologic conditions induce the onset of other concomitant diseases that need additional therapies. Combination treatment could exploit a synergism between administered drugs, increasing the effectiveness of the treatment and allowing dose reductions of the individual agents with a subsequent lower risk of toxicity. Conversely, concomitant administration of drugs may cause drug-drug interactions (DDIs), compromising treatment efficacy or increasing side effects, with a negative influence on disease progression. The choice of treatment is based on the fact that PAH is not caused by a single mechanism and that several syndromes, genetic abnormalities and environmental factors predispose to disease; therefore it is very likely that the use of treatments acting on a single pathway are not significantly effective. Moreover PAH is also frequently associated with other diseases that require concomitant clinical therapy. In this review we focused on the pharmacological treatment in PAH and related DDIs, evaluating alterations in drug transport, absorption, metabolism and excretion. This detailed analysis may be useful in clinical practice, as a better prediction of adverse events caused by DDIs in PAH improves the efficacy of combination therapy, resulting in reduced health care costs.

The impact of drug-drug interactions on pulmonary arterial hypertension therapy / R. Ciracì, G. Tirone, F. Scaglione. - In: PULMONARY PHARMACOLOGY & THERAPEUTICS. - ISSN 1094-5539. - 28:1(2014 Jan 24), pp. 1-8. [Epub ahead of print]

The impact of drug-drug interactions on pulmonary arterial hypertension therapy

R. Ciracì
Primo
;
G. Tirone
Secondo
;
F. Scaglione
2014-01-24

Abstract

In clinical practice, pulmonary arterial hypertension (PAH) requires co-administration of multiple drugs to act on several pathogenic mechanisms; chronic pathologic conditions induce the onset of other concomitant diseases that need additional therapies. Combination treatment could exploit a synergism between administered drugs, increasing the effectiveness of the treatment and allowing dose reductions of the individual agents with a subsequent lower risk of toxicity. Conversely, concomitant administration of drugs may cause drug-drug interactions (DDIs), compromising treatment efficacy or increasing side effects, with a negative influence on disease progression. The choice of treatment is based on the fact that PAH is not caused by a single mechanism and that several syndromes, genetic abnormalities and environmental factors predispose to disease; therefore it is very likely that the use of treatments acting on a single pathway are not significantly effective. Moreover PAH is also frequently associated with other diseases that require concomitant clinical therapy. In this review we focused on the pharmacological treatment in PAH and related DDIs, evaluating alterations in drug transport, absorption, metabolism and excretion. This detailed analysis may be useful in clinical practice, as a better prediction of adverse events caused by DDIs in PAH improves the efficacy of combination therapy, resulting in reduced health care costs.
Combination therapy; DDIs; PAH
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/229966
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 15
social impact